The UK and US have concluded a landmark bilateral deal that will ensure no import taxes on British pharmaceutical exports entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the public health system. This move guarantees that tariffs on these vital products will remain at nothing for a period of the next three years.
This agreement follows recent threats to hike tariffs on patented pharmaceutical products, with figures discussed up to double the cost.
"This deal with the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue equity to American-British medicine commerce," a release said.
Economic Significance
Drugs are one of the UK's biggest export categories to the America, which is clearly the primary buyer for large UK drugmakers.
Statistics show that in the one-year period to the end of the third quarter, the UK sold pharmaceutical products worth billions to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This deal protects employment, increases capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Specific NHS Changes
The deal includes several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to double overall health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must return to the NHS to control costs will be capped at fifteen percent. Last year, refunds topped 20%.
Broader Context
The deal follows a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and approval rates.
These tensions were heightened by arguments that US consumers were charged a premium for the identical medicines than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the past decade.
